Medical Stop Loss Claims Above $2 Million Have Tripled Since 2020, Report Finds

Why It Matters

Rising high‑value claims threaten employer‑sponsored health plan budgets, making deductible strategy a critical cost‑control lever. The trend signals broader inflationary pressure in U.S. healthcare that could reshape benefit design and pricing.

Key Takeaways

• $2M+ stop‑loss claims up 213% since 2020.
• Cancer accounts for 35% of paid stop‑loss claims in 2025.
• Employers who never raised deductibles saw 11% average rate hikes.
• Gene‑therapy Itvisma drives rising nervous‑system claim costs.
• Provider consolidation and AI tools amplify stop‑loss expense pressures.

Pulse Analysis

The stop‑loss market is entering a new era of volatility as claims that breach high deductibles multiply at unprecedented rates. Tokio Marine HCC’s six‑year data set shows a 213% jump in $2 million‑plus claims since 2020, driven largely by expensive oncology therapies, advanced cardiovascular interventions, and the rollout of gene‑editing treatments such as Itvisma for spinal muscular atrophy. Neonatal and perinatal cases, though fewer in number, continue to generate the largest single losses, underscoring how pediatric health risks are reshaping employer risk exposure.

A key insight from the report is the powerful influence of deductible management on premium trajectories. Employers that proactively raised their specific stop‑loss deductibles each renewal cycle limited average rate increases to roughly 2% per year, whereas those that left deductibles static faced double‑digit hikes averaging 11%. This inverse relationship reflects the leveraging effect: once a claim exceeds the deductible, all subsequent medical‑inflation trends flow directly to the stop‑loss layer, magnifying cost growth. Adjusting deductibles in line with first‑dollar medical inflation can therefore blunt premium escalation and preserve plan affordability.

Beyond individual claim drivers, systemic forces are compounding cost pressures. Provider consolidation grants health systems greater bargaining power, while AI‑enabled billing tools push reimbursement rates higher. Simultaneously, reduced federal funding for public health programs and expanding Medicare Advantage enrollment shift financial burdens onto employer‑sponsored plans. For benefits leaders, the imperative is clear: adopt dynamic deductible strategies, monitor emerging high‑cost therapies, and anticipate continued upward pressure on stop‑loss pricing through at least 2027.